Protein analytical assays for diagnosing, monitoring, and choosing treatment for cancer patients

Journal of Healthcare Engineering

Volumn 3, Issue 4, 2012, Pages 503-534

  Powers, Alicia D ^a   Palecek, Sean P ^a  

^a Wisconsin Electric Machines and Power Electronics Consortium   (United States)

Author keywords

Cancer; Diagnostic; Molecular diagnostic; Personalized cancer treatment; Protein assay

Indexed keywords

ASSAYS; DIAGNOSIS; PATIENT TREATMENT; PROTEINS;

CANCER; DIAGNOSTIC; KINASE INHIBITORS; MOLECULAR ANALYSIS; MOLECULAR DIAGNOSTICS; PREDICTIVE CAPACITY; PROTEIN ASSAYS; THERAPEUTIC EFFICACY;

DISEASES;

EID: 84871631946     PISSN: 20402295     EISSN: 20402309     Source Type: Journal    
DOI: 10.1260/2040-2295.3.4.503     Document Type: Article

References (130)

1. Pollack LA, Li J, Berkowitz Z, Weir HK, Wu XC, Ajani UA, Ekwueme DU, Li C, PB. Melanoma survival in the United States, 1992 to 2005. Journal of the American Academy of Dermatology. 2011, S78-86.
2. Bohndiek SE, Brindle KM. Imaging and "omic" methods for the molecular diagnosis of cancer. Expert review of molecular diagnostics. 2010, 10:417-34.
3. Guo R, Pan C, Shen J, Liu C. New serum biomarkers for detection of esophageal carcinoma using Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Journal of cancer research and clinical oncology. 2011, 137:513-9.
4. Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, Wells M, Guerrero M, Asara JM, Libermann T, Afdhal, NH. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clinical cancer research. 2008, 14:470-7.
5. Vlahou A, Laronga C, Wilson L, Gregory B, Fournier K, McGaughey D, Perry RR, Wright GL, Semmes OJ. A novel approach toward development of a rapid blood test for breast cancer. Clinical breast cancer. 2003, 4:203-9.
6. Galanina N, Bossuyt V, Harris LN. Molecular predictors of response to therapy for breast cancer. Cancer journal (Sudbury, Mass.). 2011, 17:96-103.
7. Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez E, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Archives of pathology & laboratory medicine. 2007, 131:18-43.
8. Hudelist G, Pacher-Zavisin M, Singer CF, Holper T, Kubista E, Schreiber M, Manavi M, Bilban M, Czerwenka, K. Use of high-throughput protein array for profiling of differentially expressed proteins in normal and malignant breast tissue. Breast cancer research and treatment. 2004, 86:281-91.
9. Gutiérrez-Xicoténcatl L, Plett-Torres T, Madrid-González CL, Madrid-Marina V. Molecular diagnosis of human papillomavirus in the development of cervical cancer. Salud pública de México. 2009, 51 (Suppl 3):S479-88.
10. Ingvarsson J, Wingren C, Carlsson A, Ellmark P, Wahren B, Engström G, Harmenberg U, Krogh M, Peterson C, Borrebaeck CK. Detection of pancreatic cancer using antibody microarray-based serum protein profiling. Proteomics. 2008, 8:2211-9.
11. Darmanis S, Nong RY, Hammond M, Gu J, Alderborn A, Vänelid J, Siegbahn A, Gustafsdottir S, Ericsson O, Landegren U, Kamali-Moghaddam M. Sensitive plasma protein analysis by microparticlebased proximity ligation assays. Molecular & cellular proteomics. 2010, 9:327-35.
12. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz PE, Mor G. Diagnostic markers for early detection of ovarian cancer. Clinical cancer research. 2008, 14:1065-72.
13. Lin D, Feng S, Pan J, Chen Y, Lin J, Chen G, Xie S, Zeng H, Chen R. Colorectal cancer detection by gold nanoparticle based surface-enhanced Raman spectroscopy of blood serum and statistical analysis. Optics express. 2011, 19:13565-77.
14. Lin J, Chen R, Feng S, Pan J, Li Y, Chen G, Cheng M, Huang Z, Yu Y, Zeng H. A novel blood plasma analysis technique combining membrane electrophoresis with silver nanoparticle-based SERS spectroscopy for potential applications in noninvasive cancer detection. Nanomedicine. 2011, 7:655-63.
15. Fromm JR, Thomas A, Wood BL. Flow cytometry can diagnose classical hodgkin lymphoma in lymph nodes with high sensitivity and specificity. American journal of clinical pathology. 2009, 131:322-32.
16. Yaziji H, Taylor CR, Goldstein NS, Dabbs DJ, Hammond EH, Hewlett B, Floyd AD, Barry TS, Martin AW, Badve S, Baehner F, Cartun RW, Eisen RN, Swanson PE. Hewitt, S. M., Vyberg, M., Hicks, D. G., Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Applied immunohistochemistry & molecular morphology. 2008, 16:513-20.
17. Hsi ED, Kopecky KJ, Appelbaum FR, Boldt D, Frey T, Loftus M, Hussein M. Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia. British journal of haematology. 2003, 120:1017-25.
18. Schmitt M, Sturmheit AS, Welk A, Schnelldorfer C, Harbeck N. Procedures for the quantitative protein determination of urokinase and its inhibitor, PAI-1, in human breast cancer tissue extracts by ELISA. Methods in molecular medicine. 2006, 120:245-65.
19. Uhrmacher S, Schmidt C, Erdfelder F, Poll-Wolbeck SJ, Gehrke I, Hallek M, Kreuzer K-A. Use of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a diagnostic tool in chronic lymphocytic leukemia (CLL). Leukemia research.2011, 35:1360-6.
20. Anderson NL, The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clinical chemistry. 2010, 56:177-85.
21. Kim MS, Kim T, Kong S-Y, Kwon S, Bae C Y, Choi J, Kim CH, Lee E S, Park J-K. Breast cancer diagnosis using a microfluidic multiplexed immunohistochemistry platform. PloS one. 2010, 5:e10441.
22. Decaestecker C, Lopez XM, D'Haene N, Roland I, Guendouz S, Duponchelle C, Berton A, Debeir O, Salmon I. Requirements for the valid quantification of immunostains on tissue microarray materials using image analysis. Proteomics. 2009, 9:4478-94.
23. Ross DT, Kim C-Y, Tang G, Bohn OL, Beck R, Ring BZ Seitz RS, Paik S, Costantino JP, Wolmark N. Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials. Clinical cancer research. 2008, 14:6602-9.
24. Ring BZ, Seitz RS, Beck Ra, Shasteen, WJ, Soltermann A, Arbogast S, Robert F, Schreeder MT, Ross DT. A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Modern pathology. 2009, 22:1032-43.
25. Kashani-Sabet M, Rangel J, Torabian S, Nosrati M, Simko J, Jablons DM, Moore DH, Haqq C, Miller JR, Sagebiel RW. A multi-marker assay to distinguish malignant melanomas from benign nevi. Proceedings of the National Academy of Sciences of the United States of America. 2009, 106:6268-72.
26. Crabb SJ, Bajdik CD, Leung S, Speers CH, Kennecke H, Huntsman DG, Gelmon K. Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study. Breast cancer research. 2008, 10:R6.
27. Grimwade L, Gudgin E, Bloxham D, Scott Ma, Erber WN. PML protein analysis using imaging flow cytometry. Journal of clinical pathology. 2011, 64:447-50.
28. Demurtas, A., Accinelli, G., Pacchioni, D., Godio, L., Novero, D., Bussolati, G., Palestro, G., Papotti, M., Stacchini, A., Utility of flow cytometry immunophenotyping in fine-needle aspirate cytologic diagnosis of non-Hodgkin lymphoma: A series of 252 cases and review of the literature. Applied immunohistochemistry & molecular morphology: AIMM / official publication of the Society for Applied Immunohistochemistry. 2010, 18:311-22.
29. D'Arena G, Musto P, Cascavilla N, Dell'Olio M, Di Renzo N, Carotenuto M. Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. American journal of hematology. 2000, 64:275-81.
30. Sun J, Masterman-Smith MD, Graham Na, Jiao J, Mottahedeh J, Laks DR, Ohashi M, DeJesus J, Kamei K-i, Lee K-B, Wang H, Yu ZTF, Lu Y-T, Hou S, Li K, Liu M, Zhang N, Wang S, Angenieux B, Panosyan E, Samuels ER, Park J, Williams D, Konkankit V, Nathanson D, van Dam RM, Phelps M E, Wu H, Liau LM, Mischel PS, Lazareff J, Kornblum HI, Yong WH, Graeber TG, Tseng H-R. A microfluidic platform for systems pathology: multiparameter single-cell signaling measurements of clinical brain tumor specimens. Cancer research. 2010, 70:6128-38.
31. Ferrier CM, de Witte HH, Straatman H, van Tienoven DH, van Geloof WL, Rietveld FJ, Sweep C G, Ruiter DJ, van Muijen GN. Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue. British journal of cancer. 1999, 79:1534-41.
32. Tan W, Sabet L, Li Y, Yu T, Klokkevold PR, Wong D T, Ho C-M. Optical protein sensor for detecting cancer markers in saliva. Biosensors & bioelectronics. 2008, 24:266-71.
33. Wang S, Zhao X, Khimji I, Akbas R, Qiu W, Edwards D, Cramer DW, Ye B, Demirci U. Integration of cell phone imaging with microchip ELISA to detect ovarian cancer HE4 biomarker in urine at the point-of-care. Lab on a chip. 2011, 11:3411-8.
34. Attallah AM, Sakr Ha, Ismail H, Abdel-Hady E-SK, El-Dosoky I. An office-based immunodiagnostic assay for detecting urinary nuclear matrix protein 52 in patients with bladder cancer. BJU international. 2005, 96:334-9.
35. Wang S, Ge L, Song X, Yu J, Ge S, Huang J, Zeng F. Paper-based chemiluminescence ELISA: lab-onpaper based on chitosan modified paper device and wax-screen-printing. Biosensors & bioelectronics. 2012, 31:212-8.
36. Ferreira CSM, Papamichael K, Guilbault G, Schwarzacher T, Gariepy J, Missailidis S. DNA aptamers against the MUC1 tumour marker: design of aptamer-antibody sandwich ELISA for the early diagnosis of epithelial tumours. Analytical and bioanalytical chemistry. 2008, 390:1039-50.
37. Liu Y, Wang H, Huang J, Yang J, Liu B, Yang P. Microchip-based ELISA strategy for the detection of low-level disease biomarker in serum. Analytica chimica acta. 2009, 650:77-82.
38. Cheow LF, Ko SH, Kim SJ, Kang KH, Han J. Increasing the sensitivity of enzyme-linked immunosorbent assay using multiplexed electrokinetic concentrator. Analytical chemistry. 2010, 82:3383-8.
39. Zhou F, Yuan L, Wang H, Li D, Chen H. Gold Nanoparticle Layer: A Promising Platform for Ultra-Sensitive Cancer Detection. Langmuir: the ACS journal of surfaces and colloids. 2011, 2155-2158.
40. Gau V, Wong D. Oral fluid nanosensor test (OFNASET) with advanced electrochemical-based molecular analysis platform. Annals of the New York Academy of Sciences. 2007, 1098, 401-10.
41. Maeng J-H, Lee B-C, Ko Y-J, Cho W, Ahn Y, Cho N-G, Lee S-HH, Seung Y. A novel microfluidic biosensor based on an electrical detection system for alpha-fetoprotein. Biosensors & bioelectronics. 2008, 23:1319-25.
42. Rauser S, Marquardt C, Balluff B, Deininger S-O, Albers C, Belau E, Hartmer R, Suckau D, Specht K, Ebert MP, Schmitt M, Aubele M, Höfler H, Walch A. Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. Journal of proteome research. 2010, 9:1854-63.
43. Hu Q, Huang Y, Wang Z, Tao H, Liu J, Yan L, Wang K. Application of Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Coupled With an Artificial Neural Network Model for the Diagnosis of Hepatocellular Carcinoma. Hepato-gastroenterology. 2011, 59.
44. Gast M-CW, Gils CHVAN, Wessels LFA, Harris N, Bonfrer JMG, Rutgers E JTH, Schellens JHM, Beijnen JH. Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS. Oncology Reports. 2009, 22:205-213.
45. Liu C. The application of SELDI-TOF-MS in clinical diagnosis of cancers. Journal of biomedicine & biotechnology. 2011, 2011:245821.
46. Szanto I, Mark L, Bona A, Maasz G, Sandor B, Gelencser G, Turi Z, Gallyas F. High-throughput screening of saliva for early detection of oral cancer: a pilot study. Technology in cancer research & treatment. 2012, 11:181-8.
47. Cornett DS, Reyzer ML, Chaurand P, Caprioli RM. MALDI imaging mass spectrometry: molecular snapshots of biochemical systems. Nature methods. 2007, 4:828-33.
48. Walter M, Heinze C, Steiner T, Pilchowski R, von Eggeling F, Wunderlich H, Junker K. Immunochemotherapy-associated protein patterns in tumour tissue and serum of patients with metastatic renal cell carcinoma. Archives of physiology and biochemistry. 2010, 116:197-207.
49. Tang K-L, Li T-H, Xiong W-W, Chen K. Ovarian cancer classification based on dimensionality reduction for SELDI-TOF data. BMC bioinformatics. 2010, 11:109.
50. Callesen AK, Vach W, Jørgensen PE, Cold S, Mogensen O, Kruse T, Jensen ON, Madsen JS. Reproducibility of mass spectrometry based protein profiles for diagnosis of breast cancer across clinical studies: a systematic review. Journal of proteome research. 2008, 7:1395-402.
51. Cadron I, Van Gorp T, Amant F, Vergote I, Moerman P, Waelkens E, Daemen A, Van De Plas R, De Moor B, Zeillinger R. The use of laser microdissection and SELDI-TOF MS in ovarian cancer tissue to identify protein profiles. Anticancer research. 2009, 29:1039-45.
52. BlokzijlA, Friedman M, Pontén F, Landegren U. Profiling protein expression and interactions: proximity ligation as a tool for personalized medicine. Journal of internal medicine. 2010, 268:232-45.
53. Schallmeiner E, Oksanen E, Ericsson O, Spångberg L, Eriksson S, Stenman U-H, Pettersson K, Landegren U. Sensitive protein detection via triple-binder proximity ligation assays. Nature methods. 2007, 4:135-7.
54. Jiang X, Cheng S, Chen W, Wang L, Shi F, Zhu C. Comparison of oligonucleotide-labeled antibody probe assays for prostate-specific antigen detection. Analytical biochemistry.2012, 424:1-7.
55. Shi Y, Huang W, Tan Y, Jin X, Dua R, Penuel E, Mukherjee A, Sperinde J, Pannu H, Chenna A, DeFazio-Eli L, Pidaparthi S, Badal Y, Wallweber G, Chen L, Williams S, Tahir H, Larson J. Goodman L, Whitcomb J, Petropoulos C, Winslow J. A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue. Diagnostic molecular pathology: the American journal of surgical pathology, part B. 2009, 18:11-21.
56. Huang W, Reinholz M, Weidler J, Yolanda L, Paquet A, Whitcomb J, Lingle W, Jenkins RB, Chen B, Larson J., Tan Y, Sherwood T, Bates M, Perez E. Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximitybased assay. American journal of clinical pathology. 2010, 134:303-11.
57. Dua R, Zhang J, Parry G, Penuel E. Detection of hepatocyte growth factor (HGF) ligand-c-MET receptor activation in formalin-fixed paraffin embedded specimens by a novel proximity assay. PloS one. 2011, 6:e15932.
58. Woodbury RL, Varnum SM, Zangar RC. Elevated HGF levels in sera from breast cancer patients detected using a protein microarray ELISA. Journal of proteome research. 2002, 1:233-7.
59. Lin JC-H. Protein microarrays for cancer diagnostics and therapy. Medical principles and practice. 2010, 19:247-54.
60. Carlsson A, Wingren C, Ingvarsson J, Ellmark P, Baldertorp B, Fernö M, Olsson H, Borrebaeck CAK. Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays. European journal of cancer. 2008, 44:472-80.
61. Strömberg S, Björklund MG, Asplund C, Sköllermo A, Persson A, Wester K, Kampf C, Nilsson P, Andersson A-C, Uhlen M, Kononen J, Ponten F, Asplund A. A high-throughput strategy for protein profiling in cell microarrays using automated image analysis. Proteomics. 2007, 7:2142-50.
62. Schröder C, Jacob A, Tonack S, Radon TP, Sill M, Zucknick M, Rüffer S, Costello E, Neoptolemos JP, Crnogorac-Jurcevic T, Bauer A, Fellenberg K, Hoheisel JD. Dual-color proteomic profiling of complex samples with a microarray of 810 cancer-related antibodies. Molecular & cellular proteomics. 2010, 9:1271-80.
63. Fang C, Wang Y, Vu NT, Lin, W-Y, Hsieh Y-T, Rubbi L, Phelps ME, Müschen M, Kim Y-M, Chatziioannou AF, Tseng H-R, Graeber TG. Integrated microfluidic and imaging platform for a kinase activity radioassay to analyze minute patient cancer samples. Cancer research. 2010, 70:8299-308.
64. Adams AA, Okagbare PI, Feng J, Hupert ML, Patterson D, Göttert J, McCarley RL, Nikitopoulos D, Murphy MC, Soper SA. Highly efficient circulating tumor cell isolation from whole blood and labelfree enumeration using polymer-based microfluidics with an integrated conductivity sensor. Journal of the American Chemical Society. 2008, 130:8633-41.
65. Du Z, Colls N, Cheng KH, Vaughn MW, Gollahon L. Microfluidic-based diagnostics for cervical cancer cells. Biosensors & bioelectronics. 2006, 21:1991-5.
66. Kim MS, Kwon S, Kim T, Lee ES, Park J-K. Quantitative proteomic profiling of breast cancers using a multiplexed microfluidic platform for immunohistochemistry and immunocytochemistry. Biomaterials. 2011, 32:1396-403.
67. Henry OY, Fragoso A, Beni V, Laboria N, Sánchez JLA, Latta D, Von Germar F, Drese K, Katakis I, O'Sullivan CK. Design and testing of a packaged microfluidic cell for the multiplexed electrochemical detection of cancer markers. Electrophoresis. 2009, 30:3398-405.
68. Sukhanova A, Nabiev I. Fluorescent nanocrystal-encoded microbeads for multiplexed cancer imaging and diagnosis. Critical reviews in oncology/hematology. 2008, 68:39-59.
69. Xie C, Wang G. Development of simultaneous detection of total prostate-specific antigen (tPSA) and free PSA with rapid bead-based immunoassay. Journal of clinical laboratory analysis. 2011, 25:37-42.
70. Long Y, Zhang Z, Yan X, Xing J, Zhang K, Huang J, Zheng J, Li W. Multiplex immunodetection of tumor markers with a suspension array built upon core-shell structured functional fluorescenceencoded microspheres. Analytica chimica acta. 2010, 665:63-8.
71. Shin K-S, Lee SW, Han K-C, Kim SK, Yang EK, Park JH, Ju B-K, Kang JY, Kim TS. Amplification of fluorescence with packed beads to enhance the sensitivity of miniaturized detection in microfluidic chip. Biosensors & bioelectronics. 2007, 22:2261-7.
72. Fu Z, Hao C, Fei X, Ju H. Flow-injection chemiluminescent immunoassay for alpha-fetoprotein based on epoxysilane modified glass microbeads. Journal of immunological methods. 2006, 312:61-7.
73. Retnakumari A, Jayasimhan J, Chandran P, Menon D, Nair S, Mony U, Koyakutty M. CD33 monoclonal antibody conjugated Au cluster nano-bioprobe for targeted flow-cytometric detection of acute myeloid leukaemia. Nanotechnology. 2011, 22:285102.
74. Ray S, Reddy PJ, Choudhary S, Raghu D, Srivastava S. Emerging nanoproteomics approaches for disease biomarker detection: a current perspective. Journal of proteomics. 2011, 74:2660-81.
75. Kah JCY, Kho KW, Lee CGL, James C., Sheppard R, Shen ZX, Soo KC, Olivo MC. Early diagnosis of oral cancer based on the surface plasmon resonance of gold nanoparticles. International journal of nanomedicine. 2007, 2:785-98.
76. Yu X, Munge B, Patel V, Jensen G, Bhirde A, Gong JD, Kim S N, Gillespie J, Gutkind JS. Papadimitrakopoulos, F., Rusling, J. F., Carbon nanotube amplification strategies for highly sensitive immunodetection of cancer biomarkers. Journal of the American Chemical Society. 2006, 128:11199-205.
77. Lin J, He C, Zhang L, Zhang S. Sensitive amperometric immunosensor for alpha-fetoprotein based on carbon nanotube/gold nanoparticle doped chitosan film. Analytical biochemistry. 2009, 384:130-5.
78. Ji NY, Kang YH, Park M-Y, Lee CI, Kim MK, Kim DG, Kim J W, Song EY. Development of a fluorescent microsphere immunoassay for cystatin B (CSTB) in serum of patients with hepatocellular carcinoma. Clinical chemistry and laboratory medicine. 2011, 49:151-5.
79. Xie C, Kim HJ, Haw JG, Kalbasi A, Gardner BK, Li G, Rao J, Chia D, Liong M, Punzalan RR, Marks LS, Pantuck AJ, de la Taille A, Wang G, Mukouyama H, Zeng G. A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from nonmalignant cases. Journal of translational medicine. 2011, 9:43.
80. Dekking E, van der Velden VHJ, Böttcher S, Brüggemann M, Sonneveld E, Koning-Goedheer A, Boeckx N, Lucio P, Sedek L, Szczepański T, Kalina T, Kovac M, Evans P, Hoogeveen PG, Flores-Montero J, Orfao A, Comans-Bitter WM, Staal FJT, van Dongen JJM. Detection of fusion genes at the protein level in leukemia patients via the flow cytometric immunobead assay. Best practice & research. Clinical haematology. 2010, 23:333-45.
81. Jokerst JV, Raamanathan A, Christodoulides N, Floriano PN, Pollard A, Simmons GW, Wong J, Gage C, Furmaga WB, Redding SW, McDevitt JT. Nano-bio-chips for high performance multiplexed protein detection: determinations of cancer biomarkers in serum and saliva using quantum dot bioconjugate labels. Biosensors & bioelectronics. 2009, 24:3622-9.
82. Lee KH, Galloway JF, Park J, Dvoracek CM, Dallas M, Konstantopoulos K, Maitra A, Searson PC. Quantitative molecular profiling of biomarkers for pancreatic cancer with functionalized quantum dots. Nanomedicine: nanotechnology, biology, and medicine. 2012.
83. Barat B, Sirk SJ, McCabe KE, Li J, Lepin EJ, Remenyi R, Koh AL, Olafsen T, Gambhir SS, Weiss S, Wu, AM. Cys-diabody quantum dot conjugates (immunoQdots) for cancer marker detection. Bioconjugate chemistry. 2009, 20:1474-81.
84. Zheng H, Chen G, DeLouise LA, Lou Z. Detection of the cancer marker CD146 expression in melanoma cells with semiconductor quantum dot label. Journal of biomedical nanotechnology. 2010, 6:303-11.
85. Hu M, Yan J, He Y, Lu H, Weng L, Song S, Fan C, Wang L. Ultrasensitive, multiplexed detection of cancer biomarkers directly in serum by using a quantum dot-based microfluidic protein chip. ACS nano. 2010, 4:488-94.
86. Kah JCY, Olivo MC, Lee CGL, Sheppard CJR. Molecular contrast of EGFR expression using gold nanoparticles as a reflectance-based imaging probe. Molecular and cellular probes. 2008, 22:14-23.
87. Liu X, Dai Q, Austin L, Coutts J, Knowles G, Zou J, Chen H, Huo Q. A one-step homogeneous immunoassay for cancer biomarker detection using gold nanoparticle probes coupled with dynamic light scattering. Journal of the American Chemical Society. 2008, 130:2780-2.
88. Lu W, Arumugam SR, Senapati D, Singh AK, Arbneshi T, Khan SA, Yu H, Ray PC. Multifunctional Oval-Shaped Gold-Nanoparticle-Based Selective Detection of Breast Cancer Cells Using Simple Colorimetric and Highly Sensitive Two- Photon Scattering Assay. ACS nanoano. 2010, 4:1739-1749.
89. Ladd J, Lu H, Taylor AD, Goodell V, Disis ML, Jiang S Direct detection of carcinoembryonic antigen autoantibodies in clinical human serum samples using a surface plasmon resonance sensor. Colloids and surfaces. B, Biointerfaces. 2009, 70:1-6.
90. Choi S, Chae J. A microfluidic biosensor based on competitive protein adsorption for thyroglobulin detection. Biosensors & bioelectronics. 2009, 25:118-23.
91. Lee K, Drachev VP, Irudayaraj J. DNA-gold nanoparticle reversible networks grown on cell surface marker sites: application in diagnostics. ACS nano. 2011, 5:2109-17.
92. Law W-C, Yong K-T, Baev A, Prasad PN. Sensitivity improved surface plasmon resonance biosensor for cancer biomarker detection based on plasmonic enhancement. ACS nano. 2011, 5:4858-64.
93. Yu C, Nakshatri H, Irudayaraj J. Identity profiling of cell surface markers by multiplex gold nanorod probes. Nano letters. 2007, 7:2300-6.
94. Piliarik M, Bocková M, Homola J. Surface plasmon resonance biosensor for parallelized detection of protein biomarkers in diluted blood plasma. Biosensors & bioelectronics. 2010, 26:1656-61.
95. Kazuno S, Fujimura T, Arai T, Ueno T, Nagao K, Fujime M, Murayama K. Multi-sequential surface plasmon resonance analysis of haptoglobin-lectin complex in sera of patients with malignant and benign prostate diseases. Analytical biochemistry. 2011, 419:241-9.
96. Mallidi S, Larson T, Tam J, Joshi PP, Karpiouk A, Sokolov K, Emelianov S. Multiwavelength photoacoustic imaging and plasmon resonance coupling of gold nanoparticles for selective detection of cancer. Nano letters. 2009, 9:2825-31.
97. Qian X, Peng X-H, Ansari DO, Yin-Goen Q, Chen GZ, Shin DM, Yang L, Young AN, Wang MD, Nie S. In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nature biotechnology. 2008, 26:83-90.
98. Lutz B, Dentinger C, Sun L, Nguyen L, Zhang J, Chmura A, Allen A, Chan S, Knudsen B. Raman nanoparticle probes for antibody-based protein detection in tissues. The journal of histochemistry and cytochemistry. 2008, 56:371-9.
99. Wang G, Lipert RJ, Jain M, Kaur S, Chakraboty S, Torres MP, Batra SK, Brand RE, Porter MD. Detection of the potential pancreatic cancer marker MUC4 in serum using surface-enhanced Raman scattering. Analytical chemistry. 2011, 83:2554-61.
100. Maiti KK, Dinish US, Fu CY, Lee J-J, Soh K-S, Yun S-W, Bhuvaneswari R, Olivo M, Chang Y-T. Development of biocompatible SERS nanotag with increased stability by chemisorption of reporter molecule for in vivo cancer detection. Biosensors & bioelectronics. 2010, 26:398-403.
101. Aydin O, Altaş M, Kahraman M, Bayrak OF, Culha M. Differentiation of healthy brain tissue and tumors using surface-enhanced Raman scattering. Applied spectroscopy. 2009, 63:1095-100.
102. Maiti KK, Samanta A, Vendrell M, Soh K-S, Olivo M, Chang Y-T. Multiplex cancer cell detection by SERS nanotags with cyanine and triphenylmethine Raman reporters. Chemical communications. 2011, 47:3514-6.
103. Chon H, Lee S, Yoon S-Y, Chang S-I, Lim DW, Choo J. Simultaneous immunoassay for the detection of two lung cancer markers using functionalized SERS nanoprobes. Chemical communications. 2011, 47:12515-7.
104. Sha MY, Xu H, Natan MJ, Cromer R. Surface-enhanced Raman scattering tags for rapid and homogeneous detection of circulating tumor cells in the presence of human whole blood. Journal of the American Chemical Society. 2008, 130:17214-5.
105. Domenici F, Bizzarri AR, Cannistraro S. SERS-based nanobiosensing for ultrasensitive detection of the p53 tumor suppressor. International journal of nanomedicine. 2011, 6:2033-42.
106. Chikkaveeraiah BV, Bhirde A, Malhotra R, Patel V, Gutkind JS, Rusling JF. Single-wall carbon nanotube forest arrays for immunoelectrochemical measurement of four protein biomarkers for prostate cancer. Analytical chemistry. 2009, 81:9129-34.
107. Malhotra R, Patel V, Vaqué JP, Gutkind JS, Rusling JF. Ultrasensitive electrochemical immunosensor for oral cancer biomarker IL-6 using carbon nanotube forest electrodes and multilabel amplification. Analytical chemistry. 2010, 82:3118-23.
108. Huang K-J, Niu D-J, Xie W-Z, Wang W. A disposable electrochemical immunosensor for carcinoembryonic antigen based on nano-Au/multi-walled carbon nanotubes-chitosans nanocomposite film modified glassy carbon electrode. Analytica chimica acta. 2010, 659:102-8.
109. Yeung D, Hughes T. Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia. Critical reviews in oncology. 2012.
110. Saintigny P, Burger JA. Recent Advances in Non-small Cell Lung Cancer Biology and Clinical Management. Discovery Medicine. n.d., 13:287-297.
111. Ghosh G, Yan X, Lee AG, Kron SJ, Palecek SP. Quantifying the sensitivities of EGF receptor (EGFR) tyrosine kinase inhibitors in drug resistant non-small cell lung cancer (NSCLC) cells using hydrogelbased peptide array. Biosensors & bioelectronics. 2010, 26:424-31.
112. Mizutani T, Kondo T, Darmanin S, Tsuda M, Tanaka S, Tobiume M, Asaka M, Ohba Y. A novel FRETbased biosensor for the measurement of BCR-ABL activity and its response to drugs in living cells. Clinical cancer research. 2010, 16:3964-75.
113. Jarvius M, Paulsson J, Weibrecht I, Leuchowius K-J, Andersson A-C, Wählby C, Gullberg M, Botling J, Sjöblom T, Markova B, Ostman A, Landegren U, Söderberg O. In situ detection of phosphorylated platelet-derived growth factor receptor beta using a generalized proximity ligation method. Molecular & cellular proteomics. 2007, 6:1500-9.
114. Ghosh G, Lee AG, Palecek SP. Hydrogel-based protein array for quantifying epidermal growth factor receptor activity in cell lysates. Analytical biochemistry. 2009, 393:205-14.
115. Lee AG, Beebe DJ, Palecek SP. Quantification of kinase activity in cell lysates via photopatterned macroporous poly(ethylene glycol) hydrogel arrays in microfluidic channels. Biomedical microdevices. 2012, 14:247-57.
116. Kim P, Liu X, Lee T, Liu L, Barham R, Kirkland R, Leesman G, Kuller A, Ybarrondo B, Ng S-C, Singh S. Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients. Proteome science. 2011, 9:75.
117. Khan IH, Zhao J, Ghosh P, Ziman M, Sweeney C, Kung H-J, Luciw P. Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells. Assay and drug development technologies. 2010, 8:27-36.
118. Lu S, Wang Y. Fluorescence resonance energy transfer biosensors for cancer detection and evaluation of drug efficacy. Clinical cancer research. 2010, 16:3822-4.
119. Lowe SB, Dick JaG, Cohen, BE, Stevens MM. Multiplex sensing of protease and kinase enzyme activity via orthogonal coupling of quantum dot-peptide conjugates. ACS nano. 2012, 6:851-7.
120. Toita R, Mori T, Naritomi Y, Kang J-H, Shiosaki S, Niidome T, Katayama Y. Fluorometric detection of protein kinase Cα activity based on phosphorylation-induced dissociation of a polyion complex. Analytical biochemistry. 2012, 424:130-6.
121. Fujiwara A, Shibata E, Terashima H, Shishido A, Nishiki J, Yoshida K, Miyauchi K, Madachi A, Matsuura N. Evaluation of matrix metalloproteinase-2 (MMP-2) activity with film in situ zymography for improved cytological diagnosis of breast tumors. Breast cancer. 2006, 13:272-8.
122. Darragh MR, Schneider EL, Lou J, Phojanakong PJ, Farady CJ, Marks JD, Hann BC, Craik CS. Tumor detection by imaging proteolytic activity. Cancer research. 2010, 70:1505-12.
123. Ryu JH., Lee A, Lee S, Ahn C-H, Park JW, Leary JF, Park S, Kim K, Kwon IC, Youn, I-C, Choi K. "One-step" detection of matrix metalloproteinase activity using a fluorogenic peptide probeimmobilized diagnostic kit. Bioconjugate chemistry. 2010, 21:1378-84.
124. Liu GL, Chen FF, Ellman Ja, Lee LP. Peptide-nanoparticle hybrid SERS probe for dynamic detection of active cancer biomarker enzymes. Conference proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Conference. 2006, 1:795-8.
125. Fajkus J. Detection of telomerase activity by the TRAP assay and its variants and alternatives. Clinica chimica acta. 2006, 371:25-31.
126. Rothacker J, Ramsay RG, Ciznadija D, Gras E, Neylon CB, Elwood NJ, Bouchier-Hayes D, Gibbs P, Rosenthal M, Nice EC. A novel magnetic bead-based assay with high sensitivity and selectivity for analysis of telomerase in exfoliated cells from patients with bladder and colon cancer. Electrophoresis. 2007, 28:4435-46.
127. Fizazi K, Morat L, Chauveinc L, Prapotnich D, De Crevoisier R, Escudier B. Cathelineau, X., Rozet, F., Vallancien, G., Sabatier, L., Soria, J. C., High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity. Annals of oncology. 2007, 18:518-21.
128. Xu T, Lu B, Tai Y-C, Goldkorn A. A cancer detection platform which measures telomerase activity from live circulating tumor cells captured on a microfilter. Cancer research. 2010, 70:6420-6.
129. Zuo X, Xia F, Patterson A, Soh HT, Xiao Y, Plaxco KW. Two-step, PCR-free telomerase detection by using exonuclease III-aided target recycling. Chembiochem. 2011, 12:2745-7.
130. Zhou X, Xing D, Zhu D, Jia L. Magnetic bead and nanoparticle based electrochemiluminescence amplification assay for direct and sensitive measuring of telomerase activity. Analytical chemistry. 2009, 81:255-61.